PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29495002-0 2018 Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53. NVP-BKM120 32-38 thymoma viral proto-oncogene 1 Mus musculus 75-78 30103709-8 2018 However, the triple combination of SN38, BKM120 and MEK162 showed a better synergistic effect that BKM120 and MEK162, indicating that the cells need to inhibit both AKT and ERK pathways to become more sensitive to irinotecan-based chemotherapies. NVP-BKM120 41-47 thymoma viral proto-oncogene 1 Mus musculus 165-168 30103709-8 2018 However, the triple combination of SN38, BKM120 and MEK162 showed a better synergistic effect that BKM120 and MEK162, indicating that the cells need to inhibit both AKT and ERK pathways to become more sensitive to irinotecan-based chemotherapies. NVP-BKM120 99-105 thymoma viral proto-oncogene 1 Mus musculus 165-168 29495002-11 2018 CONCLUSION: Our results showed that the combination of BKM120 with Prima-1Met synergistically suppressed the growth of thyroid cancer cells and tumor xenografts via inhibiting PI3K/Akt/mTOR and CPSF4/hTERT signaling and reactivating mutant p53. NVP-BKM120 55-61 thymoma viral proto-oncogene 1 Mus musculus 181-184 22037215-5 2012 NVP-BKM120 treatment decreased phosphorylation of Akt and S6 ribosomal protein (S6rp); no change in Erk1/2 phosphorylation was seen. NVP-BKM120 4-10 thymoma viral proto-oncogene 1 Mus musculus 50-53 26674543-4 2015 Our results demonstrate that BKM120 abrogates the activity of the PI3K/Akt/mTOR signaling, promoting cell growth arrest and significant apoptosis in a dose- and time-dependent manner in AML cells but not in the normal counterpart. NVP-BKM120 29-35 thymoma viral proto-oncogene 1 Mus musculus 71-74 27811010-7 2017 Because single-agent MEK inhibitors have been limited as a first-line targeted therapy due to compensatory activation of other oncogenic signaling pathways, we combined MEK162 with the PI3K/Akt inhibitor buparlisib. NVP-BKM120 204-214 thymoma viral proto-oncogene 1 Mus musculus 190-193 27623107-7 2016 Both crizotinib and BKM120 strongly inhibited the activity of MET and PI3K as evidenced by the decreased phosphorylation of MET, AKT and ribosomal S6 kinase. NVP-BKM120 20-26 thymoma viral proto-oncogene 1 Mus musculus 129-132 24799524-9 2014 BKM120 inhibits both constitutive PI3K/AKT pathway and FDC- or CXCL12-induced PI3K/AKT pathway, hampers FDC survival signaling, and reduces cell proliferation of FL cells in vitro and in mouse xenografts. NVP-BKM120 0-6 thymoma viral proto-oncogene 1 Mus musculus 39-42 24799524-9 2014 BKM120 inhibits both constitutive PI3K/AKT pathway and FDC- or CXCL12-induced PI3K/AKT pathway, hampers FDC survival signaling, and reduces cell proliferation of FL cells in vitro and in mouse xenografts. NVP-BKM120 0-6 thymoma viral proto-oncogene 1 Mus musculus 83-86 25004403-0 2014 Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. NVP-BKM120 55-61 thymoma viral proto-oncogene 1 Mus musculus 40-43 25004403-4 2014 Our aim was to determine whether the inhibition of PI3K/Akt activity by a PI3K inhibitor, BKM120, contributes to the increased sensitivity of liver cancer cells to irradiation. NVP-BKM120 90-96 thymoma viral proto-oncogene 1 Mus musculus 56-59 25004403-8 2014 BKM120 pretreatment inhibited radiation-induced Akt phosphorylation and enhanced the tumor-suppressive effect and radiation-induced tumor cell apoptosis in ectopic xenografts. NVP-BKM120 0-6 thymoma viral proto-oncogene 1 Mus musculus 48-51 25004403-10 2014 The synergism between BKM120 and irradiation likely inhibits the activation of Akt by radiation, leading to increased cell apoptosis and suppression of DNA-double-strand breaks repair in hepatocellular carcinoma cells. NVP-BKM120 22-28 thymoma viral proto-oncogene 1 Mus musculus 79-82 22469977-9 2013 Furthermore, in vivo administration of BKM120, a small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K), alleviated dyslipidemia-induced tumor growth and metastasis in Mvt-1 model with a concomitant decrease in PI3K/Akt signaling. NVP-BKM120 39-45 thymoma viral proto-oncogene 1 Mus musculus 226-229 22037215-12 2012 Overall, the results of this study demonstrated that inhibiting PI3K/Akt/mTOR signaling with the oral agents NVP-BKM120 and NVP-BEZ235 decreased mammary tumor growth in the hyperinsulinemic MKR mouse. NVP-BKM120 113-119 thymoma viral proto-oncogene 1 Mus musculus 69-72 33664847-9 2021 Vitamin C and buparlisib cooperatively blocked AKT phosphorylation. NVP-BKM120 14-24 thymoma viral proto-oncogene 1 Mus musculus 47-50 34988938-11 2022 RESULTS: Treatment with BKM120 decreased AtT-20/D16v-F2 cell viability, induced a G0/G1 cell cycle arrest, reduced the phosphorylation of Akt at Serine 473, and increased p27 expression. NVP-BKM120 24-30 thymoma viral proto-oncogene 1 Mus musculus 138-141 34988938-13 2022 CONCLUSION: In vitro inhibition of PI3K/AKT pathway by BKM120 resulted in anti-proliferative effects on corticotroph tumor cells, decreasing cell viability and ACTH production. NVP-BKM120 55-61 thymoma viral proto-oncogene 1 Mus musculus 40-43 34887852-13 2021 Furthermore, LPS and PILO exposure enhanced pAkt/Akt and phospho-p70S6/total-p70S6 kinase activity, while buparlisib and dactolisib, but not rapamycin, could reduce it in a combination model. NVP-BKM120 106-116 thymoma viral proto-oncogene 1 Mus musculus 49-52 35460881-10 2022 Together, the results suggest that repeated BKM120 treatment enhances the radial migration of DCX-positive cells and induces anxiety- and depression-like behaviors by regulating the activity of Akt, JNK, DCX, and RhoA in the dentate gyrus. NVP-BKM120 44-50 thymoma viral proto-oncogene 1 Mus musculus 194-197